Citeline Podcasts

Pink Sheet Executive Editor Derrick Gingery, Senior Editor Sue Sutter and Editor-in-Chief Nielsen Hobbs consider the implications of potential regulations that would cement the FDA’s presumption that it can release complete response letters (:49) and effectively ban direct-to-consumer advertising (18:45), as well as a potential reorganization to create a senior FDA position in charge of all medica...

Lyme disease is spreading, the last US vaccine was withdrawn in 2002, and the most recent attempt at a new one (Pfizer and Valneva's Phase III candidate) missed its primary endpoint earlier this year. Into that gap steps Tonix Pharmaceuticals with a different idea entirely: skip the vaccine and deliver the antibody directly.   In Vivo's David Wild talks to Tonix CEO Seth Lederman about TNX-4800, a...

In this podcast, Satish Reddy, chairman of Dr. Reddy's Laboratories, talks about deploying generic Revlimid gains strategically, building a diversified growth engine, what India must fix — regulatory science, risk capital and more — to become a serious innovation force, and learnings from China. A quick update for our listeners: Scrip now has its own dedicated podcast channel on Spotify and Apple...

In this episode of the China biopharma English-language podcast, Xu Hu talks about China’s drug regulator finalizing trial data protection measures for drugs registered in the country, and some of the impacts these may have on future licensing deals involving the China market and company strategies in managing product lifecycle and market access in China. Here are links to the stories this episode...

The science around the microbiome is moving fast, consumers are clearly interested, and yet the category still runs into some long-standing problems in the European Union, not least the inconsistent way the word “probiotic” itself is treated across the region. In this episode of HBW Insight’s Over the Counter podcast, we talk to Rosanna Pecere, Executive Director of IPA Europe, the European office...

비만 치료제 시장의 급성장과 일라이 릴리의 티르제파티드가 주도하는 가운데, 이벨류에이트(Evaluate)의 2026 월드 프리뷰(World Preview) 보고서에 따르면 제약 업계는 향후 몇 년 동안 새로운 매출 기록을 경신할 전망입니다(AI 기반 텍스트 음성 변환 및 음성 모방 도구의 도움을 받아 제작되었습니다) https://insights.citeline.com/scrip/market-intelligence/top-drugs/pharma-sales-to-top-2-trillion-as-the-big-drug-er...

本期播客内容来自《Scrip》杂志，精选内容涵盖截至2026年6月26日当周的生物制药行业的商业动态。本期节目采用人工智能文本转语音及语音仿真技术制作。 本期要闻: 中国交易主导BIO大会热门话题；制药企业瞄准2万亿美元销售额；Apogee助力艾伯维实现愿景；桑加莫申请破产；以及对韦伯在武田制药任职期间的回顾。 向听众们简要更新一下：Scrip现在已在Spotify和Apple Podcasts上开设了专属播客频道。 Story links: https://insights.c...

Audio roundup of selected biopharma industry content from Scrip over the business week ended June 26, 2026. This episode was produced with the help of AI text-to-voice and voice emulation tools. This time–China deal controls a hot BIO topic; pharma eyes $2tn in sales; Apogee helps AbbVie achieve vision; Sangamo files for bankruptcy; and a review of Weber’s time at Takeda.    Story links: https://i...

Pink Sheet Executive Editor Derrick Gingery, Senior Reporter Maaisha Osman and Editor-in-Chief Nielsen Hobbs discuss the potential impact of the US Food and Drug Administration’s new updated guidance describing the one-trial plus confirmatory evidence standard for effectiveness (:47) and the significance of advancing yet another priority of former Commissioner Martin Makary (6:47). They also talk...

Clinical operations plays a decisive role in execution quality, data integrity, cost control, and development speed, yet it is often treated as a cost centre rather than a strategic function. In this episode, Claire Riches, VP, Clinical Solutions, Citeline is joined by Executive Consultant, Clinical Development Operations to discuss why clinical operations must be elevated into board‑level convers...

Pancreatic cancer has the lowest survival rate of any major cancer — just 13%, largely because it's so hard to catch early. Changing that takes more than a lab breakthrough. It takes the unglamorous infrastructure to collect, track, and safeguard patient samples across dozens of institutions, reliably enough that researchers can trust what they find. In this episode, host Krishna talks with Margar...

This debut video episode of the In Vivo podcast examines the successes and pitfalls of the commercial launch of Yescarta (axicabtagene ciloleucel), Kite Pharma’s CAR-T therapy for relapsed/refractory large B-cell lymphoma. David Wild, senior reporter at In Vivo, is joined by Harris Kaplan, who consulted on the launch and conducted interviews with physicians, nurses, and hospital administrators bef...

本期播客内容来自《Scrip》杂志，精选内容涵盖截至2026年6月19日当周的生物制药行业的商业动态。本期节目采用人工智能文本转语音及语音仿真技术制作。 本期要闻: 辉瑞公司阐明肿瘤学发展方向；2026年国际生物技术大会（BIO 2026）的重点议题；GLP-1药物获取问题给肥胖症研究带来困扰；来自巴西的GLP-1药物使用洞察；以及第一季度销量前十的药物。 Story links: https://insights.citeline.com/scrip/podcasts/scrips-five-must-kno...

Audio roundup of selected biopharma industry content from Scrip over the business week ended June 19, 2026. This episode was produced with the help of AI text-to-voice and voice emulation tools. This time–Pfizer lays out oncology direction; key topics at BIO 2026; GLP-1 access causes problems for obesity studies; GLP-1 use insights from Brazil; and Q1’s top 10 drugs. Story links: https://insights....

The Generics Bulletin Podcast: Probing The Patent Monopoly With I-MAK’s Tahir Amin Description: Generics Bulletin senior reporter Urtė Fultinavičiūtė talks to Tahir Amin, co-founder and CEO of I-MAK, about the current intellectual property system that curtails off-patent drug competition and global health equity.

AI, Philips, Healthtech, Future Health Index 2026

Prevention has moved to the centre of UK health policy, with the NHS 10-year plan promising a decisive shift away from treatment. The financial case for getting there is less widely understood. In this episode of the Over the Counter Podcast, HBW Insight's David Ridley speaks to Liz Hampson, life sciences and health innovation advisory partner at Deloitte, about the firm's recent work on the socio...

Pink Sheet Editor-in-Chief Nielsen Hobbs, Senior Editor Sue Sutter, and Senior Reporter Maaisha Osman discuss the Pentagon's decision to list WuXi Apptec as a “Chinese military company” (0:58), FDA’s latest adverting enforcement letters (13:02), and the agency’s thoughts on the risks and benefits of relying on AI for regulatory activities (21:16). More on these topics from the Pink Sheet: Pentagon...

世界の製薬ビジネスを伝える「Scrip」と、各国で変化する製薬関連の規制に特化した「Pink Sheet」。普段は英語で発信する2つのオンラインメディアから、今注目の話題を日本語で短くまとめてお届けします。今回取り上げた記事はこちら：「US Drug Shortages Ease But Discontinuations Surge, Asia Supply Chain Risks Run Deep（邦訳：米国の医薬品不足は緩和も撤退数は増加、アジア由来の深いサプライチェーンリスク）」URL: http...

本期播客内容来自《Scrip》杂志，精选内容涵盖截至2026年6月12日当周的生物制药行业的商业动态。本期节目采用人工智能文本转语音及语音仿真技术制作。 本期要闻: 礼来探索Zepbound在自身免疫性疾病中的应用；阿斯利康在心血管风险管理（CVRM）领域推行互联互通战略； 阿斯利康将口服GLP-1药物推进至III期；勃林格殷格翰凭借survodutide致力于实现高质量减重；以及葛兰素史克通过收购Nuvalent扩大其肿瘤学版图。 Story links: https...

Audio roundup of selected biopharma industry content from Scrip over the business week ended June 12, 2026. This episode was produced with the help of AI text-to-voice and voice emulation tools. This time–Lilly explores Zepbound in autoimmune disorders; AstraZeneca pursues interconnected strategy in CVRM; AstraZeneca moving oral GLP-1 into Phase III; Boehringer pursues quality weight loss with sur...

Flagship Pioneering의 안드레 안도니안 아시아태평양 의장과 이병건 한국 담당 특별고문은 Scrip과의 인터뷰에서 새로운 파트너십을 모색하고, 자사의 기업 설립 모델을 국내 바이오 생태계에 적용하는 등 한국 시장 진출 전략을 공유했습니다.(AI 기반 텍스트 음성 변환 및 음성 모방 도구의 도움을 받아 제작되었습니다) Story link: https://insights.citeline.com/scrip/leadership/interviews/flagship-eyes-long-term-partn...

本期播客内容来自《Scrip》杂志，精选内容涵盖截至2026年6月5日当周的生物制药行业的商业动态。本期节目采用人工智能文本转语音及语音仿真技术制作。 本期要闻: Revolution公司的daraxonrasib在ASCO大会上引发轰动；默克公司（Merck & Co.）阐述其肿瘤学愿景；美国立法者对中美交易感到不满；ADA大会上的肥胖症治疗新挑战；以及2025年大型制药公司CEO薪酬回升。 Story links: https://insights.citeline.com/scrip/podcasts/scrips...

Audio roundup of selected biopharma industry content from Scrip over the business week ended May 29, 2026. This episode was produced with the help of AI text-to-voice and voice emulation tools. This time – can GLP-1s help in cancer; Novartis on its cardiovascular strategy; Lilly’s retatrutide looks promising in obesity; Lilly’s raises cell and gene therapy bet; and the business impact of China’s n...

Audio roundup of selected biopharma industry content from Scrip over the business week ended June 5, 2026. This episode was produced with the help of AI text-to-voice and voice emulation tools. This time – Revolution’s daraxonrasib makes splash at ASCO; Merck & Co. lays out oncology vision; US legislators bristle over US-China deals; obesity challengers at ADA; and big pharma CEO pay rebounds in 2...